Quotient Clinical’s Chief Scientific Officer awarded honorary professorship at the University of Nottingham
Quotient Clinical, the Translational Pharmaceutics® Company, has announced that Dr Peter Scholes, its Chief Scientific Officer, has been awarded an honorary professorship in the School of Pharmacy at the University of Nottingham…
Quotient Clinical, the Translational Pharmaceutics® Company, has announced that Dr Peter Scholes, its Chief Scientific Officer, has been awarded an honorary professorship in the School of Pharmacy at the University of Nottingham. The award recognizes distinguished individuals who have strengthened links between the University and practical experience in business and industry, through seminars, lectures and research collaborations.
Mark Egerton, CEO Quotient Clinical, said: “We are delighted that Peter has received this award and recognition. Peter joined our business in 2007 and has played a key role in developing Translational Pharmaceutics and its application to drug development. He is passionate about the quality of science that we undertake, and holds himself and his colleagues accountable to the highest standards. On behalf of everyone at Quotient, I would like to offer Peter our warmest congratulations”.
Peter added: “I am deeply honored to receive this recognition from the University of Nottingham. My six years of studying there had a hugely positive influence on my future, and I hold the School of Pharmacy, the University and its staff in the utmost regard. It has been highly rewarding to maintain my links with the School during my career as I believe that strong relationships between industry and academia are critical, both for developing scientists of the future, and for directing innovative research to improve patient-centred treatment outcomes. I look forward to maintaining my association with the University in the years ahead”.
http://www.quotientclinical.com/
